Treatment of Lupus Nephritis with anti-CD20 Followed by Anti-BAFF: Impact on B Cell Reconstitution, B Cell Subsets, and Autoreactivity

被引：0
|
作者：
Fregoso, Yemil Atisha [1 ]
Malkiel, Susan [1 ]
Harris, Kristina [2 ]
Kanaparthi, Sai [2 ]
Byron, Margie [3 ]
Ding, Linna [4 ]
Smilek, Dawn [5 ]
Wofsy, David [6 ]
Dall'Era, Maria [7 ]
Aranow, Cynthia [1 ]
Diamond, Betty [1 ]
机构：
[1] Feinstein Inst Med Res, Manhasset, NY USA
[2] Immune Tolerance Network, Bethesda, MD USA
[3] Rho Fed Syst Inc, Chapel Hill, NC USA
[4] NIAID, 9000 Rockville Pike, Bethesda, MD 20892 USA
[5] Immune Tolerance Network, San Francisco, CA USA
[6] UCSF, San Francisco, CA USA
[7] Univ Calif San Francisco, San Francisco, CA 94143 USA
来源：
ARTHRITIS & RHEUMATOLOGY | 2019年 / 71卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
0941
引用
收藏
页数：4
相关论文
共 50 条
  • [21] Ofatumumab, a Novel Anti-CD20 Monoclonal Antibody for the Treatment of B-Cell Malignancies
    Cheson, Bruce D.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (21) : 3525 - 3530
  • [22] Effects of anti-CD20 treatment beyond B cell depletion: Reduction of endogenous sTACI
    Mader, Simone
    Thaler, Franziska
    Fichtner, Miriam
    Ho, Samantha
    Oswald, Eva
    Wong, Hoi Kiu
    Vural, Atay
    Yilmaz, Vuslat
    Tuezuen, Erdem
    Turkoglu, Recai
    Straub, Tobias
    Smolle, Michalea
    Schaller, Jonas
    Feederle, Regina
    Bultmann, Andreas
    Schneider, Pascal
    Meinl, Ingrid
    Kuempfel, Tania
    Meinl, Edgar
    MULTIPLE SCLEROSIS JOURNAL, 2023, 29 : 592 - 593
  • [23] Anti-CD20 monoclonal antibody as a new treatment modality for B-cell lymphoma
    Hotta, T
    ACTA HISTOCHEMICA ET CYTOCHEMICA, 2002, 35 (04) : 275 - 279
  • [24] New Anti-CD20 Monoclonal Antibodies for the Treatment of B-Cell Lymphoid Malignancies
    Robak, Tadeusz
    Robak, Ewa
    BIODRUGS, 2011, 25 (01) : 13 - 25
  • [25] New Anti-CD20 Monoclonal Antibodies for the Treatment of B-Cell Lymphoid Malignancies
    Tadeusz Robak
    Ewa Robak
    BioDrugs, 2011, 25 : 13 - 25
  • [26] Successful treatment of B-cell prolymphocytic leukemia with monoclonal anti-CD20 antibody
    Abou Mourad, Y
    Taber, A
    Chehal, A
    Shamseddine, A
    ANNALS OF HEMATOLOGY, 2004, 83 (05) : 319 - 321
  • [27] Anti-CD20 treatment for B-cell malignancies: current status and future directions
    Klein, Christian
    Jamois, Candice
    Nielsen, Tina
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2021, 21 (02) : 161 - 181
  • [28] Successful treatment of B-cell prolymphocytic leukemia with monoclonal anti-CD20 antibody
    Yasser Abou Mourad
    Ali Taher
    Aref Chehal
    Ali Shamseddine
    Annals of Hematology, 2004, 83 : 319 - 321
  • [29] B cell populations in the myasthenia thymus that bind Rituximab (anti-CD20)
    Zainudeen, Z.
    Attfield, K.
    Willcox, N.
    Vincent, A.
    IMMUNOLOGY, 2014, 143 : 186 - 186
  • [30] Effector mechanisms of anti-CD20 monoclonal antibodies in B cell malignancies
    Okroj, Marcin
    Osterborg, Anders
    Blom, Anna M.
    CANCER TREATMENT REVIEWS, 2013, 39 (06) : 632 - 639
12345